American Capital Advisory’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
American Capital Advisory's RPRX Position: Q2 2026 in Review
American Capital Advisory increased its Royalty Pharma (RPRX) stake by 1.6% in Q2 2026, buying an estimated $416 and bringing the position to 524 shares worth $29.4K. The position accounts for 0.01% of the portfolio, ranked #268.
American Capital Advisory first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. The position peaked at $36K in Q1 2024. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.
- American Capital Advisory held 524 shares of Royalty Pharma worth $29.4K as of Q2 2026.
- American Capital Advisory bought 8 Royalty Pharma shares in Q2 2026, an estimated $416.
- Royalty Pharma made up 0.01% of American Capital Advisory's portfolio in Q2 2026, its #268 holding.
- American Capital Advisory first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
- American Capital Advisory's Royalty Pharma position peaked at $36K in Q1 2024.
- 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.
Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.